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1. Introduction 
“Let food be your medicine and medicine be your food” stated Hippocrates, the father of 
Western medicine, in 400 B.C. This statement was based on the belief that food was able to 
influence disease, a concept that was revived several times in later years by painters, writers, 
scientists, and philosophers. One such philosopher, Ludwig Feuerbach, famously wrote in his 
1863-4 essay “man is what he eats” introducing the idea that if we want to improve the spiritual 
conditions of people we must first improve their material conditions (Feuerbach, 2003). 
However, for years his warnings remained unheeded, at least in Western countries, in contrast 
to the teachings of Indian and Chinese medicine which for millennia have argued that a living 
organism has to assume a healthy diet. Like diet, physical activity has been also considered an 
important starting point for people's health. Hippocrates wrote in his book Regimen "if we could 
give every individual the right amount of nourishment and exercise, not too little and not too 
much, we would have found the safest way to health" (Hippocrates, 1955). Our knowledge 
about the links between diet, exercise, and disease has vastly increased since Hippocrates time. 
A healthy lifestyle based on diet and physical activity is now considered the keystone of disease 
prevention and the basis for a healthy aging. However, modern society has created conditions 
with virtually unrestricted access to food resources and reduced physical activity, resulting in a 
positive overall energy balance. This is far from the environment of our ”hunter-gathered 
ancestros” whose genes were modulated over thousands of years adapting our metabolism to 
survive when food was scarce and maximizing energy storage when food became available. In 
terms of evolution, this radical and sudden lifestyle change in modern society has led to a 
dramatic increase in the incidence of metabolic diseases including obesity and type 2 diabetes 
mellitus (T2DM). It seems clear that the development of T2DM has a genetic component that 
becomes obvious when individuals are exposed to western lifestyle. However, environment 
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plays a critical role in the incidence of the disease being obesity the main etiological cause of 
T2DM. Thus, modest weight loss is enough for obese glucose intolerant subjects to prevent the 
development of T2DM (National Task Force on the Prevention and Treatment of Obesity, 2000). 
T2DM also known as “non-insulin-dependent diabetes mellitus” or “adult-onset diabetes”, is a 
metabolic disorder characterized by high blood glucose, insulin resistance, and relative insulin 
deficiency. T2DM is diagnosed when fasting blood glucose levels are higher than 126 mg/dL 
(7.0 mM) or the two-hour blood glucose levels higher than 200 mg/dL (11.1 mM) after a 
glucose tolerance test. T2DM is now considered to be a global epidemic with significant social 
and economic consequences both at the individual and population level. The International 
Diabetes Federation estimates that 366 million people suffered from this disease in 2011 and 
predicts that these numbers will increase to 552 million people by 2030. Risk factors for T2DM 
include genetic predisposition as well as environmental factors, including adverse intrauterine 
environment, inactivity, diet, obesity, and aging (International Diabetes Federation, 
http://www.idf.org/diabetesatlas/news/fifth-edition-release). 
The term "prediabetes" is used to describe a condition characterized by impaired glucose 
tolerance or impaired fasting glucose (Pour and Dagogo-Jack, 2011). The pathophysiology of 
prediabetes is characterized by alterations in insulin sensitivity and pancreatic beta-cell 
function, usually associated with increased adiposity (Dagogo-Jack et al., 2009). According 
to the World Health Organization (WHO) and the American Diabetes Association (ADA), 
impaired glucose tolerance is defined as a two-hour plasma glucose level between 140 and 
199 mg/dL (7.8 to 11.0 mmol/L) after an oral glucose tolerance test. In this condition, fasting 
glucose levels may be either normal or mildly elevated. The ADA defines a state of impaired 
fasting glucose when fasting plasma glucose levels are over 100 mg/dL (5.6 mmol/L) but less 
than 125 mg/dL (6.9 mmol/L). Importantly, subjects with prediabetes are at higher risk for 
progressing to diabetes. Fortunately, such progression is not inevitable and can be delayed 
or prevented through pharmacological and lifestyle interventions based on diet and exercise 
(Knowler et al., 2002, Knowler et al., 2009, Tuomilehto et al., 2001). While these data are 
encouraging, these interventions are costly, require a very high degree of commitment of the 
subjects, and are not always successful. Although the progress in understanding the 
metabolic derangements of T2DM has led to significant advances in the treatment of this 
disease, it remains unclear whether current therapeutic approaches can really improve the 
underlying metabolic defects. Therefore, there is an urgent need to characterize the complex 
pathophysiology of the disease, to identify and target specific mechanisms in order to slow 
down the worldwide diabetes epidemic. 
2. Insulin action and insulin resistance 
Insulin essentially provides an integrated set of signals that allow for the balancing of 
nutrient availability and caloric demands (Samuel et al., 2010). In collaboration with the 
opposing hormone glucagon, it is responsible for maintaining glucose homeostasis, which is 
necessary to ensure proper function and survival of all organs. The regulation of plasma 
glucose concentrations is vital for the entire body and both hypoglycemia and 
hyperglycemia can impair whole-body physiology, ultimately leading to cellular death. This 
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is why it is critical to regulate and maintain plasma glucose levels around 5mM, the 
physiological set point in mammals (Saltiel, 2001). 
The primary targets of insulin action to maintain glucose homeostasis are skeletal muscle, 
liver, and adipose tissue. Under physiological conditions, carbohydrates provided by the 
diet increase plasma glucose levels and promote insulin secretion from pancreatic β cells of 
the islets of Langerhans. Once secreted, insulin binds to its receptor, triggering a cascade of 
downstream phosphorylation events that expand the initial signal (Figure 1). Insulin binds 
to its receptor and activates its intrinsic protein tyrosine kinase activity, resulting in the 
phosphorylation of tyrosine residues located in the cytoplasmic face. The activated receptor, 
in turn, recruits and phosphorylates a group of substrate molecules. They have the role of 
docking proteins and are known as “insulin receptor substrates” (IRS). Among these, IRS1 
and IRS2 appear to be the major adapter molecules that play a role in insulin cascade. IRS1/2 
can activate different intracellular processes, above all glucose metabolism and mitogenesis. 
Once phosphorylated, these docking proteins recruit the heterodimeric p85/p110-PI3K at the 
plasma membrane: the regulatory subunit p85 binds to IRS1/2 and this event allows the 
activation of the catalytic subunit p110, which produces the lipid second messenger PIP3 
from PIP2. PIP3 activates a serine/threonine phosphorylation cascade of PH-domain 
containing proteins: PDK1, the serine/threonine protein kinase B (PKB)/Akt and the atypical 
protein kinases C ζ and λ isoforms (aPKC ζ - λ). Specifically, PKB phosphorylation causes: 
1. activation of the mammalian target of rapamycin (mTOR), an intracellular protein as 
well as a critical component of the PI3K/AKT pathway, that acts as a central regulator of 
multiple signaling pathways that mediate growth, proliferation and cell differentiation; 
2. glycogen synthase kinase-3 (GSK3) inactivation. This event relieves the inhibitory 
phosphorylation of glycogen synthase (GS), which becomes activated and promotes 
glycogen synthesis; 
3. insulin-stimulated translocation of the glucose transporter GLUT4 at the plasma 
membrane, resulting in increased glucose uptake. This pathway involves the protein 
AS160/TBC1D4. AS160 normally inhibits translocation of GLUT4 through its interaction 
with RabGTPase protein. The inhibitory phosphorylation of AS160 favors the GTP-loaded 
state of Rab and relieves the inhibitory effect on GLUT4, stimulating its translocation to 
the plasma membrane. In this way, insulin can promote the docking and fusion of 
GLUT4-containing vesicles to the plasma membrane and finally stimulate glucose uptake. 
Insulin action in normal conditions differs depending on the target tissue: 
 in skeletal muscle, it increases glucose transport, increasing glucose uptake and 
activating glycogen synthesis; 
 in liver, it promotes glycogen synthesis and de novo lipogenesis, while inhibiting 
gluconeogenesis; 
 in adipose tissue, it suppresses lipolysis and promotes lipogenesis, leading to a net 
increase in lipid accumulation. 
Insulin secretion from pancreatic β cells is suppressed during fasting. During this state, 
there is an increase in hepatic glucose production and glycogenolysis. Lipid synthesis 
diminishes in liver while lipolysis increases in adipose tissue. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 260 
 
IRS, insulin receptor substrate; S, serine; Y, tyrosine; PH, pleckstrin homology domain of the IRS-1; SHC, Src 
Homology 2 domain; GRB2, growth factor receptor-bound protein 2; ERK, extracellular-signal-regulated kinases or 
classical MAP kinases; PIP2, phosphatidylinositol 4,5-bisdiphosphate; PIP3, phosphatidylinositol 3,4,5-tridiphosphate; 
PDK1, phosphoinositide-dependent protein kinase 1; PKB/Akt, protein kinase B; mTOR, mammalian target of 
rapamycin; GSK3, glycogen synthase kinase 3; GS, glycogen synthase; AS160, 160 kDa Akt substrate; GDP, guanosine 
diphosphate; GTP, guanosine triphosphate; aPKC, atypical protein kinase C. 
Figure 1. Insulin signaling pathway 
3. Pathogenesis of Type 2 Diabetes Mellitus 
An important early phenotype associated with increased T2DM risk is insulin resistance. 
Insulin resistance, defined as reduced responsiveness to the effects of insulin to promote 
glucose disposal into muscle, liver and adipose tissue, is present in high-risk individuals years 
before the onset of T2DM, and can predict the development of the disease (Martin et al., 1992, 
Tabak et al., 2009). Given these data, it is alarming that the high prevalence of insulin 
resistance in the population predicts further dramatic increases in the worldwide epidemic of 
T2DM. Individuals with established T2DM show several physiological abnormalities, 
including elevation in fasting glucose levels, elevation in postprandial glucose levels, or both. 
Insulin resistance in adipose tissue, skeletal muscle, and liver, together with pancreatic beta-
cell dysfunction represent the core pathophysiologic defects of T2DM (DeFronzo, 1988). 
In the initial stages of development of T2DM, insulin is not able to correctly stimulate 
skeletal muscle glucose uptake after carbohydrate intake, leading to postprandial 
hyperglycemia. In adipose tissue, the major fat storage tissue in mammals, insulin resistance 
results in increased lipolysis and fatty acid release. Increased circulating fatty acids decrease 
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the ability of insulin to suppress hepatic glucose production and allow a constant increase in 
fatty acid synthesis. This dysregulation of carbohydrate and lipid metabolism accelerates the 
progression of insulin resistance. During the first stages of the development of the disease, 
pancreatic beta-cells have the ability to compensate for insulin resistance by increasing basal 
and postprandial insulin secretion to correct hyperglycemia. When pancreatic beta-cells can 
no longer compensate they become unable to respond appropriately to glucose levels. This 
pancreatic beta-cell failure leads to the deterioration of glucose homeostasis and the 
development of T2DM. This pattern of physiological abnormalities in skeletal muscle, 
adipose tissue, liver, and pancreas presents itself in the late stages of the disease (Saltiel, 
2001). Additionally, abnormal secretion and regulation of incretins in the gastrointestinal 
tract, hyperglucagonemia due to alterations in pancreatic alpha-cells, increased glucose 
reabsorption in kidney, and altered balance of central nervous system pathways involved in 
food intake and energy expenditure play an important role in the development of T2DM 
(Defronzo, 2009). This complex pathophysiology makes difficult to identify the primary 
events responsible for the development of T2DM. 
4. Skeletal muscle insulin resistance and T2DM 
As mentioned above, insulin resistance is a key component for the development of T2DM. 
However, the underlying molecular mechanisms are still unclear. Himsworth and Kerr, 
using a combined oral glucose and intravenous tolerance test, were the first to 
demonstrate that tissue-specific insulin sensitivity was lower in T2DM individuals 
(Himsworth, 1940). Ginsberg and colleagues provided another important evidence related 
to the decreased ability of insulin to promote glucose uptake in subjects with T2DM 
(Ginsberg et al., 1975). Later on, clear evidences about skeletal muscle insulin resistance in 
T2DM subjects were provided by DeFronzo and colleagues, who used the euglycemic-
hyperinsulinemic clamp technique to quantify insulin-stimulated glucose uptake. With 
this technique, in a series of studies DeFronzo and colleagues demonstrated that both lean 
and obese T2DM subjects have marked decrease in whole body glucose disposal during 
the insulin clamp (DeFronzo, 1988). Skeletal muscle is the largest insulin-sensitive organ 
in humans accounting for more than 80% of insulin stimulated glucose disposal 
(DeFronzo et al., 1985). Therefore, insulin resistance in this tissue has major consequences 
on whole-body metabolic homeostasis. 
Several mechanisms have been proposed as potential contributors to insulin resistance in 
skeletal muscle, including accumulation of intracellular lipid derivatives (diacylglycerol and 
ceramides), endoplasmic reticulum stress, impaired gene transcription, and pro-
inflammatory signals (Ozcan et al., 2004, Straczkowski et al., 2007, Patti et al., 2003, Timmers 
et al., 2008, Sell et al., 2006). Moreover, several evidences linked mitochondrial defects to 
insulin resistance and T2DM (Lowell and Shulman, 2005), suggesting that these organelles 
are key players in maintaining energy homeostasis. 
In this chapter we will discuss the potential role that mitochondrial dysfunction plays in 
T2DM etiology. In addition, a critical review of the current status of the topic will be 
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presented. In order to facilitate the reader the understanding of this chapter content we will 
briefly introduce several aspects of skeletal muscle composition, metabolism, mitochondria 
biogenesis and regulatory machinery that are necessary to comprehend subsequent 
information. 
4.1. Skeletal muscle fiber types and metabolism 
Skeletal muscle is a complex tissue composed of different fiber types, which have distinct 
mechanical and metabolic properties. Adult mammalian skeletal muscle is organized in motor 
units. Each of these functional systems is composed of a motor neuron and a group of muscle 
fibers. There are four major fiber types in mammalian skeletal muscle, categorized based on 
their myosin heavy chain (MyHC) composition: type 1 (slow oxidative), type 2A (fast-twitch 
oxidative), type 2X (fast-twitch oxidative-glycolytic), and type 2B (fast-twitch glycolytic). In 
adult human skeletal muscle type 2B fibers are not detectable and the oxidative capacity of type 
2X fibers is lower than that observed in rats and mice (Schiaffino and Reggiani, 2011). For 
additional reading we recommend a review published in Physiological Reviews written by 
Stefano Schiaffino and Carlo Reggiani that provides an up to date and detailed understanding 
of this topic (Schiaffino and Reggiani, 2011). For the purposes of this discussion, it is important 
to keep in mind skeletal muscle diversity: distinct skeletal muscle fibers differ in their energy 
requirements for cellular function, including contractile activity. Energy is provided by 
adenosine triphosphate (ATP) hydrolysis to adenosine diphosphate (ADP) and inorganic 
phosphate (Pi). ATP can be generated by three main mechanisms that vary in their capacity and 
velocity to resynthesize ATP. The Phosphocreatine (PCr)-creatine kinase (CK) system 
corresponds to a high-power and low-capacity ATP production reservoir. Glycolysis is the 
metabolic process by which glycogen and glucose are metabolized to pyruvate and 
subsequently to lactate; this process has a lower power but a higher capacity for ATP generation 
than the PCr-CK system. The other energy production resource is the mitochondrial oxidative 
phosphorylation system, which can obtain ATP from different substrates: pyruvate, fatty acids, 
amino acids, and ketone bodies. The oxidative phosphorylation system has a very high capacity 
for ATP generation but a lower power when compared to the other two ATP production 
systems. It is also important to highlight that mitochondrial mediated ATP resynthesis is highly 
dependent on oxygen and substrate availability. 
Due to its intrinsic characteristics, slow and fast muscle fibers differ in their relative contribution 
to energy production from PCr-CK, glycolysis, and oxidative phosphorylation processes. The 
relative contribution of these metabolic pathways is mostly established during differentiation 
according to the specific function and energy demands of each fiber type. Moreover, it is 
important to mention that adult skeletal muscle fibers show what has been termed “metabolic 
flexibility.” Metabolic flexibility is the systemic capacity to switch between different substrates 
for ATP production depending of their availability and energy requirements (Kelley et al., 1999, 
Storlien et al., 2004). Thus, skeletal muscle is able to predominantly utilize both glucose and free 
fatty acids as fuel sources for energy production. The utilization of these two energy sources 
depends on the fasting/feeding state of the individual: 
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 During fasting state, muscle glucose uptake is low and plasma fatty acid concentration 
is elevated due to lipolysis in adipose tissue. Thus, under fasting conditions, fatty acids 
represent the main source for energy production in skeletal muscle. 
 During feeding state, plasma glucose concentration increases and stimulates insulin 
secretion that exerts two principal and simultaneous actions: suppression of lipolysis in 
adipose tissue, leading to a reduction in plasma fatty acid concentration, and 
stimulation of glucose uptake in skeletal muscle. This event, together with the 
activation of key enzymes in glucose metabolism, leads to a marked increase in muscle 
glucose oxidation. After glucose is transported into the myocytes trough the GLUT4 
transporter, it is immediately phosphorylated by hexokinase II, and the phosphorylated 
glucose is stored as glycogen or enters the glycolytic pathway for energy production. 
Thus, during feeding conditions, the main source for energy production in skeletal 
muscle is glucose. 
Therefore, muscle energy metabolism has to be capable of switching from predominant 
oxidation of fatty acids during fasting state, to predominant oxidation of glucose during 
feeding state. However, obese and type 2 diabetic subjects are unable to shift between 
substrates (fatty acids or glucose) demonstrating a high degree of metabolic inflexibility 
(Kelley et al., 1999). This inability to oxidize one substrate or another results in impaired 
glucose and fatty acid storage as glycogen and triglycerides, respectively. These concepts of 
metabolic flexibility and inflexibility are documented by studies performed by Dave Kelley 
and co-workers (Kelley et al., 1999, Kelley et al., 2002a, Kelley et al., 2002b) and summarized 
by Storlien et al. in the “Proceedings of the Nutrition Society” (Storlien et al., 2004). 
4.2. Pathogenesis of Insulin Resistance in Skeletal Muscle 
Both obese subjects with or without T2DM have marked skeletal muscle insulin resistance 
compared to lean non-diabetic subjects. The severity of the insulin resistance positively 
correlates with BMI (DeFronzo, 1982, Wedick et al., 2009). The mechanism through which 
obesity causes insulin resistance in skeletal muscle seems to be associated with the 
accumulation of fatty acids in the myocytes. Among the various types of fatty acids, 
saturated long-chain ones, including palmitic and stearic acids, are strong inducers of 
insulin resistant state (Hirabara et al., 2009). Obese subjects with or without T2DM are 
characterized by an increase in plasma fatty acid concentration, which strongly correlates 
with reduced insulin-stimulated glucose disposal in skeletal muscle. 
In normal conditions, fatty acids are stored in the adipose tissue as triglycerides and 
released during fasting. During the postprandial state, blood glucose stimulates insulin 
secretion, which inhibits lipolysis in adipose tissue, therefore limiting the release of fatty 
acids. In insulin resistant individuals, the ability of insulin to inhibit lipolysis and reduce 
plasma fatty acid concentration is markedly impaired (Groop et al., 1991). This leads to a 
chronic activation of lipolysis and higher plasma fatty acid levels. Several studies have 
demonstrated that chronically elevated plasma fatty acid levels cause insulin resistance in 
skeletal muscle(Bajaj et al., 2005, Boden, 1997). 
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One of the proposed mechanisms to explain how fatty acids impair glucose oxidation in 
skeletal muscle was postulated by Randle and colleagues more than 40 years ago (Randle et 
al., 1963). They observed that incubation of rat heart with fatty acids was associated with an 
increase in intracellular concentrations of glucose-6-phosphate (G6P) and glucose. 
Moreover, incubation of diaphragm muscle with fatty acids led to an increase in glycogen 
accumulation. According to “Randle’s Theory”, fatty acid oxidation increases the ratios 
acetyl coenzyme A/coenzyme A and NADH/NAD+ in the mitochondria, leading to the 
inactivation of pyruvate dehydrogenase (PDH). Accumulation of citrate inhibits 
phosphofructokinase and increases intracellular concentrations of G6P, leading to activation 
of glycogen synthesis, inhibition of hexokinase II, increase in intracellular glucose content 
and, consequently, reduction in glucose uptake. Thus, this model is based on the inverse 
relationship between fatty acid availability and glucose utilization. Increase free fatty acid 
availability inhibits glucose utilization through inhibition of key enzymes involved in 
glucose metabolism. 
In contrast with Randle’s hypothesis, Roden and colleagues (Roden et al., 1996) 
demonstrated that a reduction in muscle glycogen synthesis by elevated fatty acids 
concentration occurred after a decrease in muscle glucose-6-phosphate levels. Thus, these 
results demonstrate that free fatty acids induce insulin resistance in humans by initial 
inhibition of glucose transport/phosphorylation, which is then followed by a reduction in 
both the rate of muscle glycogen synthesis and glucose oxidation. Therefore, according to 
Roden et al., insulin resistance induced by fatty acids is primarily associated with impaired 
glucose uptake rather than glucose accumulation (Roden et al., 1996). 
To establish which of these two possible effects takes place, Dresner and colleagues (Dresner 
et al., 1999) measured intra-myocellular concentrations of free glucose in healthy people 
under conditions of high and low plasma fatty acids concentrations. If there was a block at 
the hexokinase step, as proposed by Randle, intra-myocellular glucose concentrations would 
be expected to increase. Instead, they noted that plasma fatty acid concentrations decreased 
the accumulation of intra-myocellular glucose, indicating that insulin-stimulated glucose 
transport activity was reduced. These results, like others carried out by Cline and colleagues 
(Cline et al., 1999), confirmed Roden’s work and suggested that in people with T2DM 
impairment of insulin action in skeletal muscle is due to reductions in insulin-stimulated 
glucose transport rather than glucose accumulation. 
A second mechanism proposed to explain the pathogenesis of skeletal muscle insulin 
resistance is related to endoplasmic reticulum (ER) stress (Hotamisligil, 2010). ER is an 
intracellular membranous network responsible for synthesis, folding, maturation, trafficking 
and targeting of secreted and transmembrane proteins. It also plays a critical role as a 
regulator of Ca+ homeostasis and lipid biosynthesis. In some diseases, protein synthesis 
increases in ER-lumen and proteins cannot fold correctly, affecting ER homeostasis. 
Impairment of ER homeostasis activates an elaborate adaptive stress response, known as 
“unfolded protein response” (UPR), and results in the phosphorylation and activation of 
JNK. The link between T2DM, insulin resistance and ER stress in skeletal muscle is still 
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unclear. It has been demonstrated that ER stress occurs in vivo in skeletal muscle when mice 
are fed a high fat diet (Deldicque et al., 2010a). In another study (Deldicque et al., 2010b), the 
same authors observed that subjects on high fat diet had increased lipid content and insulin 
resistance in skeletal muscle with no change in ER stress markers. 
Inflammation has also been proposed as a potential mechanism involved in the 
development of impaired insulin sensitivity. Fatty acids activate inflammatory signals by 
promoting secretion of pro-inflammatory cytokines including TNFalpha, IL-1beta, and IL-6. 
Furthermore, fatty acids can directly interact with members of the Toll-like receptor (TLR) 
family, promoting activation of JNK and IKKbeta. This activation leads to degradation of the 
inhibitor of kappa beta (IKB) and Nuclear factor-kappa beta (NFKB) activation. This is 
associated with a decrease in insulin action due to the phosphorylation of IRS-1. A study 
carried out by Tsukumo and co-workers demonstrated that mice containing a loss of 
function mutation in the tlr4 gene (toll-like receptor 4) were partially protected from lipid-
induced muscle inflammation (Tsukumo et al., 2007), highlighting the importance of this 
receptor in skeletal muscle insulin sensitivity. 
5. Biology of the mitochondria 
Mitochondria are doubled-membrane organelles that constitute the major site for oxidative 
energy production in the cell. Mitochondria are the only mammalian organelles that contain 
extra-nuclear DNA (mtDNA), which encodes for 37 genes including 13 subunits of the electron 
transport chain (Kelly and Scarpulla, 2004). Besides generating the majority of cellular ATP via 
oxidative phosphorylation (OXPHOS), many other essential cellular functions take place in 
this organelle. Examples of these include the generation of numerous metabolites via the 
tricarboxylic acid (TCA) cycle, oxidative catabolism of amino acids and fatty acids, synthesis of 
ketone bodies, ornithine cycle (also known as the urea cycle), control of cytoplasmic reticulum 
and calcium signaling (Murgia et al., 2009, Rimessi et al., 2008), synthesis of cellular Fe/S 
clusters that are essential cofactors for protein translation and DNA repair (Lill and 
Muhlenhoff, 2008) and generation of reactive oxygen species (ROS) with important signalling 
functions (Starkov, 2008, Murphy, 2009) and potential damaging consequences. 
5.1. Oxidative phosphorylation (OXPHOS) 
Mitochondria are able to generate energy by oxido-reduction reactions and proton 
translocation derived from carbohydrates (TCA cycle), amino acids and fatty acids (β-
oxidation). For this purpose, oxygen is consumed to generate water, heat and adenosine 
triphosphate (ATP). The inner membrane invaginations of the mitochondria, called cristae, 
contain all transmembrane proteins of the electron transfer system (ETS) and the ATP 
synthase (Benard and Rossignol, 2008, Vonck and Schafer, 2009). All components of the TCA 
cycle and β-oxidation pathway are located inside the mitochondrial matrix. Oxidation of 
substrates generates reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin 
adenine dinucleotide (FADH2) that will provide electrons to the ETS. Four different 
complexes –named from complex I to complex IV- form the ETS. Electrons flow from donors 
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(NADH at complex I and FADH2 at complex II) to an oxygen molecule forming H2O at 
complex IV. There is a parallel translocation of protons to the intermembrane space from the 
matrix that creates an electrochemical gradient used by ATP synthase in a coupled manner to 
generate ATP. This electrochemical gradient can also dissipate through uncoupling proteins 
(UCPs) using a non-ATPase-coupled proton leak and generating heat in a process called 
thermogenesis. The high electronegative potential generated can also drive the entry of 
calcium into the matrix. Another phenomenon is the loss of electrons during the ETS that can 
result in generation of reactive oxygen species. 
5.2. Mitochondrial biogenesis and dynamics 
Mitochondrial biogenesis is defined as the generation of more mitochondrial mass and takes 
place in response to increased energy demand. These organelles have a heterogeneous 
morphology due to its dynamic nature. Mitochondrial dynamics is a relatively novel 
concept that includes movement of mitochondria along the cytoskeleton, regulation of 
mitochondrial architecture (morphology and distribution), and connectivity mediated by 
tethering and fusion/fission events (Liesa et al., 2009). Mitochondrial fusion/fission events 
allow the transcriptional products of mtDNA along with multiple metabolites to be shared 
within the mitochondrial reticulum. It has been recently established that mitochondrial 
fission and fusion contribute to multiple essential functions including calcium handling, 
ROS production and energy output (Chen and Chan, 2005, Parone et al., 2008, Soubannier 
and McBride, 2009). The relevance of these events in mitochondrial and cell physiology has 
been partially unraveled and observed that the disruption of such processes results in 
mitochondrial heterogeneity and dysfunction (Zorzano et al., 2009, Chan, 2006). Therefore, a 
fine-tune regulation of mitochondrial biogenesis and dynamics is necessary to obtain and 
maintain functional mitochondria. 
Mitochondrial biogenesis is a complex process that requires the expression of a large 
number of proteins encoded by both nuclear and mitochondrial genomes. The 
mitochondrial genome encodes only 13 proteins, which are essential subunits of the 
respiratory complexes. This genome also provides the 22 tRNAs and 2 rRNAs necessary for 
the translation of these mitochondrial-encoded proteins. In contrast, transcription of the 
mitochondrial genome is encoded by the nuclear genome, which is under the control of a 
single transcription factor named TFAM. Other components needed for the transcription of 
the mitochondrial genome, including POLRMT, TFB1M, TFB2M, and mTERF are also 
encoded by nuclear genes. Therefore, fine-tuned coordination is required between the 
mitochondrial and the nuclear genomes to orchestrate the expression of proteins necessary 
for a successful mitochondrial biogenesis. This coordination is achieved by complex 
regulatory mechanisms that involve the action of a relatively small number of nuclear 
transcription factors, which are discussed in detail below. These transcription factors are in 
turn regulated by cofactors that integrate physiological signals with the activity of the 
transcription factors to regulate mitochondrial biogenesis in response to environmental 
stimuli. Among the most important cofactors are the PGC-1 coactivator family members, 
which are also discussed in more detail below (Kelly and Scarpulla, 2004). 
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5.3. Nuclear transcription factors involved in mitochondrial biogenesis 
Through their DNA-binding domain, transcription factors bind to specific sequences in the 
gene promoter region to regulate transcription of a subset of genes. Several transcription 
factors have been shown to regulate expression of genes involved in the respiratory chain 
and mitochondrial metabolism, however only a few are considered the major transcription 
factors crucial for mitochondrial biogenesis.  
5.3.1. Nuclear Respiratory Factor 1 (NRF-1) 
NRF-1 has a fundamental role in coordinating nuclear and mitochondrial transcription. It 
induces expression of TFAM, TFB1M and TFB2M (Virbasius and Scarpulla, 1994, Gleyzer 
et al., 2005), which are essential proteins for the transcription of the mitochondrial 
genome, and also TOMM20, a key protein required for the transport of nuclear-encoded 
proteins into the mitochondria. It has also been shown to regulate multiple subunits of the 
respiratory chain as well as other proteins involved in other mitochondrial functions. 
Disruption of the NRF-1 gene in mouse models results in mtDNA depletion and impaired 
mitochondrial membrane potential with an early embryonic lethal phenotype (Huo and 
Scarpulla, 2001). 
5.3.2. Nuclear Respiratory Factor 2 (NRF-2/GABP) 
A second nuclear respiratory factor was identified based on its ability to induce expression 
of a subunit of cytochrome c oxidase, COXIV, and was found to be a complex of the DNA-
binding subunit alpha (GABPalpha) and four other subunits (beta1, beta2, gamma1, and 
gamma2). This respiratory factor was named NRF-2 and was subsequently identified as the 
human homolog of the mouse GABP (Virbasius et al., 1993). NRF-2 has been shown to 
regulate expression of key proteins involved in mitochondrial biogenesis and function, 
including TFAM, TFB and all cytochrome C oxidase isoforms (Gleyzer et al., 2005, 
Ongwijitwat and Wong-Riley, 2005, Virbasius et al., 1993). Similarly to NRF-1, disruption of 
the NRF-2 gene also produces a lethal phenotype (Ristevski et al., 2004).  
5.3.3. Estrogen-Related Receptor alpha (ERRalpha) 
ERRalpha mediates expression of a wide range of genes, including those responsible for 
fatty acid uptake and oxidation as well as genes for oxidative phosphorylation (Mootha et 
al., 2004, Huss et al., 2002). Although structurally related to the estrogen receptor, 
ERRalpha does not bind estrogen. Instead, it is a member of a family of orphan nuclear 
receptors that also include ERRbeta and ERRgamma. Unlike NRF-1 and NRF-2 where 
gene knockout proves lethal, disruption of ERRalpha results in a viable phenotype 
showing decreased body weight and adipose depot size (Luo et al., 2003). This mouse 
shows normal energy expenditure with no major decrease in mitochondrial proteins. This 
can be explained by compensation by the other members of the transcription factor 
family. 
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5.3.4. Other transcription factors 
While not directly involved in transcription of mitochondrial biogenesis or respiratory chain 
genes, other transcription factors including PPARalpha, PPARdelta, and YY1 are also 
important for providing other mitochondrial proteins. PPARalpha is responsible for 
expression of lipid metabolism and mitochondrial fatty acid oxidation genes (Lee et al., 
1995, Leone et al., 1999). Through inducible tissue-specific loss of function knockout mouse 
models, PPARdelta has been shown to regulate mitochondrial biogenesis in skeletal muscle 
and heart (Schuler et al., 2006, Wang et al., 2010). Finally, YY1 has been shown to activate 
cytochrome c expression (Seelan and Grossman, 1997, Basu et al., 1997) as well as several 
key genes for mitochondrial respiration (Cunningham et al., 2007). 
5.3.5. PGC-1 coactivator family 
While the transcription factors discussed above are part of the transcriptional machinery 
necessary for mitochondrial biogenesis, the members of the PGC-1 coactivator family 
provide the integration of physiological stimuli with the transcription factors to adapt 
mitochondrial biogenesis to changes in the environment. PGC-1 coactivators lack a DNA-
binding domain, but they are able to interact with and activate several transcription 
factors by recruiting other cofactors with chromatin-remodeling activities (Monsalve et 
al., 2000). PPARgamma coactivator 1alpha (PGC-1alpha), the founding member of the 
PGC-1 family, was first identified by its ability to activate PPARgamma in brown 
adipocytes (Puigserver et al., 1998). PGC-1beta and PRC where subsequently identified 
based on their structural similarity with PGC-1alpha (Lin et al., 2002a, Andersson and 
Scarpulla, 2001). Interestingly, NRF-1, NRF-2, ERRalpha, YY1 and the PPAR family 
members are among the transcription factors the PGC-1 family members are able to 
coactivate (Wu et al., 1999, Cunningham et al., 2007), underlying the importance of these 
coactivators in the regulation of mitochondrial biogenesis. This role of PGC-1alpha and 
PGC-1beta in mitochondrial gene expression is well documented in gain of function 
experiments, where increased expression of these coactivators in skeletal muscle results in 
an induction of a wide array of genes involved in mitochondrial biogenesis and function 
(Wu et al., 1999, Lin et al., 2002b, Arany et al., 2007). Furthermore, muscle-specific 
disruption of PGC-1alpha gene in mice shows decreased expression of mitochondrial 
genes, resulting in a switch from oxidative fibers to more glycolytic fibers, impairing their 
endurance capacity (Handschin et al., 2007). 
PGC-1alpha is highly regulated at both the transcriptional level and post-translational level, 
primarily through phosphorylation (Jäger et al., 2007, Li et al., 2007, Rodgers et al., 2010) and 
acetylation (Lerin et al., 2006, Rodgers et al., 2005). It is this regulatory capacity that allows 
PGC-1alpha to respond to physiological stimuli and activate the mechanisms leading to 
increased mitochondrial biogenesis. PGC-1alpha activity is determined by its acetylation 
status, regulated by the balance between acetylation mainly by the histone acetyltransferase 
GCN5 (Lerin et al., 2006) and deacetylation largely by the NAD+ dependent deacetylase 
SIRT1 (Rodgers et al., 2005). This acetylation/deacetylation regulatory mechanism is 
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involved in the integration of nutrient sensing with transcriptional regulation of 
mitochondrial genes in skeletal muscle (Gerhart-Hines et al., 2007). In this context, caloric 
restriction has been proposed to increase mitochondrial biogenesis at least in part through 
activating SIRT1 and inducing PGC-1alpha deacetylation increasing its transcriptional 
activity (Baur et al., 2006, Lagouge et al., 2006). Physical exercise has also been recognized as 
a main activator of mitochondrial biogenesis. In the muscle cell, the AMP-dependent protein 
kinase (AMPK) responds to low energy levels (increase in AMP content) by inducing a 
signaling cascade that results in the activation of catabolic pathways and inhibition of 
anabolic pathways in an attempt to restore energy levels. Therefore, AMPK has been 
recognized as a key mediator in the physiological and metabolic adaptation to physical 
exercise. Interestingly, AMPK can directly phosphorylate PGC-1alpha and activate its 
transcriptional activity regulating expression of mitochondrial genes (Jäger et al., 2007). 
Furthermore, it has been recently shown that AMPK activation results in a net increase of 
NAD+ levels with the consequent induction of SIRT1 activity and PGC-1alpha deacetylation 
(Canto et al., 2010). 
6. Mitochondrial dysfunction as a potential mechanism underlying 
skeletal muscle insulin resistance 
Mitochondrial adaptations (biogenesis and dynamics) and function largely affect muscle 
metabolism and have a significant impact on whole-body metabolism (Patti et al., 2010). As 
mentioned before, metabolic flexibility is defined as the ability to rapidly modulate 
substrate oxidation as a function of environmental, hormonal and different energy 
conditions (Storlien et al., 2004). Defects in pathways controlling glucose and energy 
homeostasis in skeletal muscle have been shown to impair these adaptations, leading to 
metabolic inflexibility. What it is important for the role played by mitochondrial 
dysfunction in T2DM etiology is that this state of metabolic inflexibility is a hallmark of the 
development of skeletal muscle insulin resistance (Storlien et al., 2004). 
Mitochondrial dysfunction is a term that could imply several definitions due to the multiple 
functions that take place in this organelle. For the purposes of this chapter, we will define 
mitochondrial dysfunction as both the reduction in mitochondrial oxidative activity and in 
mitochondrial adenosine triphosphate (ATP) synthesis. Although mitochondrial dysfunction 
is related to a broad range of diseases, in this chapter we will focus on mitochondrial 
respiratory dysfunction related to muscle insulin resistance and T2DM etiology. 
6.1. Early evidences relating insulin resistance and skeletal muscle 
mitochondrial dysfunction 
Several key studies published between 1999 and 2005 laid the foundation for understanding 
the underlying mechanisms between mitochondrial dysfunction and subsequent insulin 
resistance in skeletal muscle and development of T2DM. Significant results from these 
studies are summarized below. 
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6.1.1. Dysregulation of skeletal muscle fat oxidation in obesity 
The first studies that identified a relationship between alterations in muscle metabolism and 
insulin resistance did not mention any link with mitochondrial dysfunction (Kelley et al., 
1999). However, research performed by Kelley and co-workers addressed why the pattern of 
fatty acid utilization in skeletal muscle during fasting conditions might be associated with 
obesity-related insulin resistance, which is relevant for the scope of this chapter. The study 
included 16 lean and 40 obese volunteers with leg balance measurements of glucose and free 
fatty acid uptake. Indirect calorimetry across the leg was also measured in order to 
determine substrate oxidation during fasting and insulin-stimulated conditions. This study 
demonstrated that fatty acids were the predominant substrate oxidized by skeletal muscle 
during fasting conditions in lean subjects. However, rates of fatty acid oxidation during 
fasting were significantly lower in obese subjects, even though rates of fatty acid uptake 
were similar to those of lean subjects. Furthermore, the respiratory quotient values across 
the leg showed a reduced reliance on lipid oxidation in obese subjects. What it is also 
important is that weight loss only partially improved these patterns; the leg respiratory 
quotient in obese subjects was unchanged between pre- and post-weight loss, so the reliance 
of skeletal muscle in fat oxidation during fasting conditions was not improved. The authors 
suggested that their data pointed to these defects as primary impairments leading to 
obesity, rather than resulting from obesity. Based on these data and previous observations 
from the same group (Kelley et al., 1993, Kelley et al., 1999) it could be concluded that the 
elevated intra-myocellular lipid accumulation in skeletal muscle of obese subjects derives 
from a reduced capacity for fatty acid oxidation, and this inflexibility in regulating fatty acid 
oxidation rates, more than fatty acid uptake itself, is related to insulin resistance. 
6.1.2. Muscle mitochondria in obesity and type 2 diabetes 
In this study, Kelley and co-workers provided early evidence that mitochondrial dysfunction in 
human skeletal muscle contributes to the development of insulin resistance and progression to 
T2DM (Kelley et al., 2002b). Previous work by the same group demonstrated that the severity of 
skeletal muscle insulin resistance in T2DM and obesity is related to diminished activity of 
oxidative enzymes (Simoneau and Kelley, 1997). Furthermore, triglyceride accumulation in 
skeletal muscle is also correlated with the severity of insulin resistance and with diminished 
oxidative enzyme activity. Because it was known that skeletal muscle depends on oxidative 
phosphorylation to produce energy and that insulin resistance in T2DM and obesity involves 
altered oxidation of carbohydrates and lipids, the authors attempted to elucidate the potential 
contribution of mitochondrial dysfunction to skeletal muscle insulin resistance in humans. For 
this purpose vastus lateralis muscle samples from lean controls without T2DM, obese subjects 
with or without T2DM were obtained. An assessment of the activity of the mitochondrial 
OXPHOS system and a quantitative study of the mitochondria morphology by transmission 
electron microscopy was performed in the different muscle biopsies. Creatine kinase and citrate 
synthase activities were measured as markers of muscle fiber content and mitochondrial 
content, respectively. Results showed that skeletal muscle mitochondria structure and 
functional capacity were impaired in T2DM subjects and, to a lesser degree, in obese subjects. 
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Mitochondrial respiratory complex I activity was reduced by 40% in skeletal muscle from 
subjects with T2DM when compared to lean controls without diabetes. Moreover, skeletal 
muscle mitochondrial area and size were smaller in obesity and T2DM and, in some instances, 
particularly in T2DM, severely damaged. Although age can affect the size of mitochondria, in 
this case aging did not account for the ~30% reduction in size in obesity and T2DM. 
Based on their results, authors proposed a potential mechanism that could explain how 
impaired mitochondrial function leads to insulin resistance in skeletal muscle, which would 
be lipid accumulation within myocytes. This was not a new finding, as previous studies 
(Kelley et al., 2002a) from the same group had shown that increased lipid accumulation in 
skeletal muscle is associated with insulin resistance and, in turn, lipid accumulation in 
skeletal muscle in obesity and T2DM is related to a reduced oxidative enzyme activity. 
Therefore, based on their findings, the authors stated that impaired mitochondrial 
functional capacity in skeletal muscle can lead to insulin resistance and further T2DM. 
6.1.3. Downregulation of oxidative metabolism genes in humans with insulin resistance 
and diabetes 
Patti and colleagues addressed how gene regulation was modulated by T2DM (Patti et al., 
2003). High-density oligonucleotide arrays were performed using mRNA samples from 
skeletal muscle of people with or without T2DM and with prediabetes (insulin-resistant 
subjects at high risk for T2DM) to identify genes differentially expressed. The results 
showed that skeletal muscle from subjects with prediabetes and T2DM had decreased 
expression of oxidative phosphorylation genes, many of which are regulated by nuclear 
respiratory factor (NRF)-dependent transcription. A decreased expression of the co-
activators PGC-1alpha and PGC-1beta, both of which induce NRF-dependent transcription, 
was also found. Therefore, subjects with insulin resistance and T2DM have a reduced 
expression of multiple (NRF-1)-dependent genes encoding key enzymes in oxidative 
metabolism and mitochondrial function. It seems that PGC-1 expression may be responsible 
for decreased expression of NRF-dependent genes due to alterations in the primary 
sequence and environmental risk factors for T2DM such as aging, fiber type composition, 
insulin resistance itself and inactivity, subsequently leading to the metabolic disturbances 
characteristic of insulin resistance and T2DM. 
6.1.4. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately 
downregulated in human diabetes 
This study extended the results obtained by Patti and colleagues (Patti et al., 2003). Mootha 
and co-workers used Gene Set Enrichment Analysis, designed to detect modest but 
coordinated changes in the expression of groups of functionally related genes to study 
differential expression among healthy individuals, impaired glucose tolerance subjects, and 
subjects with T2DM (Mootha et al., 2003). They named OXPHOS-CR to a subset of genes, 
which include about two-thirds of the OXPHOS genes, strongly expressed in skeletal muscle, 
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heart and brown adipose tissue. No relationship was found between body mass index (BMI) 
or waist-to-hip ratio and OXPHOS-CR expression, and neither between quantitative measures 
of fiber types and OXPHOS-CR. However, expression of OXPHOS-CR correlated positively 
with the aerobic capacity of the individuals under study and negatively to diabetes. In 
summary, a set of genes involved in oxidative phosphorylation, whose expression was 
coordinately decreased in skeletal muscle of T2DM subjects, were identified. Thus, authors 
hypothesized that the decreased expression of OXPHOS-CR genes might contribute to T2DM. 
Expression of this gene set was induced by PGC-1alpha, which expression is higher in tissues 
of insulin-mediated glucose disposal and correlated with total body aerobic capacity. 
6.1.5. Impaired mitochondrial activity in insulin-resistant offspring of subjects with T2DM 
In this study Petersen and co-workers aimed to determine the potential mechanism for the 
intra-myocellular accumulation of lipids leading to insulin resistance (Petersen et al., 2004). 
As previously stated, increases in intra-myocellular triglyceride content can occur as a result 
of increased delivery of fatty acids from lipolysis and/or decreased rates of mitochondrial 
oxidative phosphorylation. Young and lean insulin-resistant offspring of subjects with 
T2DM and insulin-sensitive subjects were studied. To test their hypotheses, authors utilized 
hyperinsulinemic-euglycemic clamps in these subjects to measured intra-myocellular lipid 
and intrahepatic triglyceride content, assessed whole-body and subcutaneous fat lipolysis 
rates and determined mitochondrial oxidative-phosphorylation activity in muscle by 
magnetic resonance spectroscopy. The insulin-stimulated rate of glucose uptake was 60% 
lower in the insulin-resistant subjects, which could be explained by a 70% reduction in 
insulin-stimulated non-oxidative muscle glucose metabolism. They also observed an 80% 
increase in intra-myocellular lipid content and a 30% reduction in mitochondrial oxidative 
phosphorylation, suggesting that subjects with T2DM have an inherited reduction in 
mitochondrial content in muscle, which in turn may be responsible for the reduced rates of 
mitochondrial oxidative phosphorylation. In summary, their data supports the hypothesis 
that insulin resistance in skeletal muscle of insulin-resistant offspring of subjects with T2DM 
is linked to an impairment of fatty acid metabolism, potentially due to an inherited defect in 
mitochondrial oxidative phosphorylation (Petersen et al., 2004). 
6.2. Putting the pieces together, the link between mitochondrial dysfunction and 
T2DM 
In the year 2005 Drs. Lowell and Shulman wrote a viewpoint where they hypothesized that 
insulin resistance and hyperglycemia could be caused by a primary mitochondrial 
dysfunction (Lowell and Shulman, 2005). Insulin resistance occurs due to the accumulation 
of intracellular fatty acyl CoA and diacylglycerol, which in turn activate critical signal 
transduction pathways, leading to suppression of the insulin signaling pathway. Among the 
metabolic perturbations that caused accumulation of fatty acids in liver and/or skeletal 
muscle and defects in the ability of these organs to metabolize fatty acids, mitochondrial 
dysfunction seemed to be the reason for inducing insulin resistance. The suggested 
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hypothesis was that insulin resistance in humans arises from defects in mitochondrial fatty 
acid oxidation, which in turn lead to increases in intracellular fatty acid metabolites such as 
fatty acyl CoA and diacylglycerol that disrupt insulin signaling pathway (Figure 2). 
 
OXPHOS, oxidative phosphorylation; CI-CII-CIII-CIV complexes I, II, III and IV within the oxidative phosphorylation 
system; CytC, cytocrome C; TCA, tricarboxylic acid cycle;NADH, nicotinamide adenine dinucleotide; FADH2, flavin 
adenine dinucleotide (hydroquinone form); ATP, adenosine triphosphate; ADP, adenosine diphosphate; Pi, inorganic 
phosphate; DAG, diacylglycerol; Thr, threonine; Ser,S, serine; Tyr,Y, tyrosine; IRS-1, insulin receptor substrate 1; PIP2, 
phosphatidyil inositol 2; PH, pleckstrin homology domain of the IRS-1; PIP3, phosphatidyl inositol 3; SH2, Src 
homology 2 domain; Akt, also known as protein kinase B; GLUT4, glucose transported type 4. 
Figure 2. Fat-induced insulin resistance hypothesis in skeletal muscle. 
T2DM and obesity characterize by chronic nutrient oversupply that can lead to an increase of 
reducing equivalents (NADH and FADH2) which increases the flux through the oxidative 
respiratory system (OXPHOS) in the inner membrane in the mitochondria and, in the absence 
of increased ATP demand, results in ROS generation creating oxidative stress. ROS increased 
concentration would lead to a diminished mitochondrial density/content or an inherited 
condition that in turn lead to a mitochondrial dysfunction and consequent decrease in beta-
oxidation increasing the intra-myocellular long-chain fatty acids and diacylglycerol (DAG) 
concentrations. DAG would then activate the phosphorylation of serines and threonines of the 
insulin receptor susbtrate 1 (IRS-1) through enzymes such as protein kinases C (PKC). PKCs 
activate the serine kinase cascade and increase the IRS-1 serine (Ser, S) phosphorylation of the 
the insulin receptor susbtrate 1 (IRS-1). The phosphorylation of serines located in critical sites 
leads to a blockage of the IRS-1 tyrosines (Tyr, Y) phosphorylation by the insulin receptor, 
inhibiting insulin-induced phosphatidyl inositol 3-kinase activity (PI3-kinase) resulting in a 
decreased insulin-stimulated Akt activity. Akt reduced activity fails to activate the 
translocation of GLUT4 to the membrane, diminishing the insulin-induced glucose uptake and 
impairing the removing of glucose from blood. 
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It is still uncertain whether skeletal muscle mitochondrial dysfunction is a cause or rather a 
consequence of the metabolic derangements that contribute to insulin resistance in T2DM, 
including lipid accummulation, pro-inflammatory signals or endoplasmic reticulum stress. 
However, given its complex pathophysiology, establishing causality has proved difficult 
and the mechanisms leading to insulin resistance remain elusive. 
7. Current status of the topic 
It is well established that mice and rats with a chronic exposure to a high fat diet (HFD) 
develop obesity, insulin resistance and, in the long term, T2DM (Oakes et al., 1997, Surwit et 
al., 1988). Furthermore, it has been shown that skeletal muscle mitochondrial content is 
diminished in T2DM individuals (Patti et al., 2003, Kelley et al., 2002b). These features, 
together with impaired energy substrate utilization and the observation that these 
deleterious effects are not restricted to skeletal muscle, led to the hypothesis that 
mitochondrial dysfunction plays a major role in T2DM etiology (Lowell and Shulman, 2005). 
Since the publication of this hypothesis, there has been a growing interest in further 
assessing the potential implication of mitochondrial function in the etiology of this 
metabolic disease. One of the first attempts to clearly prove this hypothesis used transgenic 
mice with defective mitochondria in order to observe whether they would develop T2DM 
(Pospisilik et al., 2007). Earlier reports from this same group have shown that conditional 
deletion of apoptosis inducing factor (AIF) provokes OXPHOS dysfunction (Vahsen et al., 
2004). Initially, AIF was considered as a mitochondrial protein involved in signaling events 
leading to cell death. Subsequent studies have demonstrated that the primary physiological 
role of AIF is the maintenance of an efficient mitochondrial respiratory system. Studies 
assessing whole body glucose homeostasis and diet-induced obesity and diabetes either in 
tissue specific (liver and skeletal muscle) AIF knockout mice or in mice with ubiquitous 
OXPHOS defects showed that these mice were more insulin sensitive and were protected 
against diet-induced obesity and diabetes, in contrast with previous hypotheses (Pospisilik 
et al., 2007). Recently, this observation has been confirmed in another study using rats fed 
with an iron-deficient diet, which provokes a reduction in the iron containing proteins of 
OXPHOS (Han et al., 2011). Thus, rats under a high fat and iron-deficient diet are protected 
against high fat diet-induced insulin resistance in skeletal muscle despite a lower fatty acid 
oxidation capacity (Han et al., 2011). 
7.1. Controversy about the effects of high fat diet feeding in skeletal muscle 
oxidative capacity 
In 2007, two different studies were published addressing whether a high fat diet (HFD) 
decreases or improves skeletal muscle mitochondrial oxidative capacity. In one (Garcia-
Roves et al., 2007), rats were fed with a HFD during 4 weeks in order to raise circulating 
fatty acids and therefore to study the mechanisms that regulate the already reported 
improved fatty acid oxidation capacity of glycolytic skeletal muscle. Rats fed with the HFD 
regime showed higher fatty acids content, increased skeletal muscle fatty acid oxidative 
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capacity in the epitrochlearis (glycolytic muscle), increased expression of enzymes of the 
fatty acid oxidation pathway and increased protein content of carboxylic acid cycle and 
OXPHOS system markers. Furthermore, this study showed that this metabolic adaptation 
occurs through activation of the peroxisome proliferated activated receptor delta 
(PPARdelta), a nuclear receptor responsible for regulating transcription of enzymes that 
belong to the fatty acid oxidation pathway and mitochondrial biogenesis process. Fatty 
acids, mostly unsaturated, are ligands and activators of PPARs, which explain the metabolic 
regulations observed in this study (Garcia-Roves et al., 2007). Similar results were 
published, almost simultaneously, by Cooney and colleagues in mice (Turner et al., 2007). 
C57BL/6J mice were on a HFD either for 5 or 20 weeks. In both periods of time HFD mice 
showed an increased capacity to oxidize fatty acid in skeletal muscle, concomitantly with an 
increased enzymatic activity of key proteins in the fatty acid oxidation pathway and higher 
protein content of different mitochondrial markers. Most importantly, these improvements 
in fatty acid handling and mitochondrial respiration in fat-fed mice occurred at the time 
these animals showed skeletal muscle insulin resistance and impaired whole body glucose 
handling (Turner et al., 2007). These observations were corroborated in the same study 
using a rat model of obesity (Zucker rats on a HFD) or a mouse model of diabetes and 
obesity, the db/db mouse (Turner et al., 2007). One year later Holloszy’s laboratory, in a 
follow-up of Garcia-Roves’ study, showed that rats fed with two different high fat diets 
(50% of energy from flax seed/olive oil or lard/corn oil) had skeletal muscle insulin 
resistance with improved mitochondrial content (Hancock et al., 2008). Therefore, results 
from these studies led researchers to question whether mitochondrial dysfunction plays a 
major role in the etiology of T2DM. It seems more probable that skeletal muscle insulin 
resistance per se or skeletal muscle inactivity could be the origin of the observed decrease in 
mitochondrial content in subjects with T2DM. 
As described over these lines it is uncertain whether skeletal muscle mitochondrial 
dysfunction plays a critical role in the development of T2DM. We continue the chapter 
presenting the more recent studies on this topic. First, we will address human based studies 
and afterwards recent animal studies that provide some relevant information into the field. 
7.2. Human studies 
It is important to note that in skeletal muscle two different mitochondrial populations exist: 
subsarcolemmal and intermyofibrillar. Subsarcolemmal mitochondria are located beneath 
the sarcolemma and have a lower oxidative rate than intermyofibrilar mitochondria. 
Furthermore, both mitochondrial populations play different roles in skeletal muscle 
metabolism and, therefore, respond differently to physiological or pathophysiological 
situations (Palmer et al., 1977). Kelley and coworkers compared both skeletal muscle 
mitochondrial subpopulations in lean, obese, and T2DM subjects (Ritov et al., 2005). The 
main observation of this study was that the electron transfer system was dramatically 
reduced in the subsarcolemmal mitochondrial population in obese subjects, and even to a 
higher degree in T2DM subjects when compared to lean controls. However, physical activity 
level was not controlled, therefore it is unknown whether differences in mitochondrial 
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activity could be related to this parameter. Thus, the authors concluded that an impaired 
subsarcolemmal mitochondrial activity may have a critical role in the pathogenesis of 
insulin resistance in T2DM (Ritov et al., 2005).  
Similar conclusions are obtained in a study carried out by Schrauwen-Hinderling and 
colleagues (Schrauwen-Hinderling et al., 2007) where they attempted to distinguish between 
the relevance of intra-myocellular lipid content and mitochondrial dysfunction in skeletal 
muscle insulin resistance. For this purpose, they compared overweight subjects with high 
intra-myocellular lipid content to weight-matched T2DM subjects. The study showed that 
T2DM subjects had impaired mitochondrial function and similar levels of intra-myocellular 
lipid content when compared to weight-matched controls. These data provide more 
evidence supporting the link between mitochondrial dysfunction and T2DM, although they 
do not imply causality (Schrauwen-Hinderling et al, 2007). Similar results were found in a 
subsequent study where Ritov and colleagues compared mitochondrial function in lean, 
obese and obese-T2DM subjects (Ritov et al., 2010). Along with this idea, Shulman and co-
workers performed a study on insulin resistant offspring of T2DM subjects. Offspring 
subjects with insulin resistance showed a decreased oxidative phosphorylation capacity and 
increased intra-myocellular lipid content. These results led the authors to conclude that a 
limited mitochondrial fatty acid oxidative capacity leads to an increased lipid accumulation 
and subsequently to skeletal muscle insulin resistance. However, the mechanism by which 
skeletal muscle intralipid accumulation leads to insulin resistance needs still to be 
elucidated (Befroy et al, 2007). Conversely, in another study performed in subjects with and 
without T2DM (Asmann et al., 2006), mitochondrial ATP production rate under controlled 
insulin and glucose levels at the post-absorptive state (low glucose, low insulin levels) and 
post-pandrial state (high glucose, high insulin levels) was evaluated. The authors found no 
major differences between subjects with and without T2DM at the post-absortive state. A 
lower response in the mitochondrial ATP production rate when insulin and glucose rose to 
achieve post-pandrial state values was observed in T2DM subjects. This study showed how 
skeletal muscle mitochondrial defects are not intrinsic in subjects with T2DM but are related 
to impaired insulin action (Asmann et al., 2006). Thus, it is difficult to discern whether 
mitochondrial dysfunction is a cause or rather a consequence of skeletal muscle insulin 
resistance due to the cross-sectional nature of most of the human studies carried out. 
In 2007 Dela and co-workers added some relevant information to the field using high 
resolution respirometry to compare skeletal muscle mitochondrial function between T2DM 
and control subjects (Boushel et al., 2007). T2DM subjects showed a reduced OXPHOS and 
electron transport capacity when compared to control individuals, as previously observed. 
However, when the respiratory parameters were normalized by mitochondrial content the 
authors observed that T2DM subjects did not show mitochondrial dysfunction (Boushel et 
al., 2007). Therefore, skeletal muscle respiratory capacity could be diminished in T2DM 
subjects due to a reduction in mitochondrial content and not due to specific defects in the 
respiratory phosphorylation system. As mentioned before, the observation of a reduced 
mitochondrial content could be due to a lack of physical activity rather than to a genetic 
defect in these insulin resistant individuals. These results, showing that T2DM subjects have 
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similar mitochondrial respiratory capacity when normalized by mitochondrial content, were 
corroborated by a later study performed in lean and obese insulin resistant subjects by 
Mandarino and co-workers (Lefort et al., 2010). When mitochondrial function was assessed 
in isolated skeletal muscle mitochondria from lean and obese-insulin resistant subjects a 
similar maximal respiration rate was observed in both groups. However, obese-insulin 
resistant subjects showed a higher reactive oxygen species (ROS) production, which could 
influence insulin signaling. Additional information was obtained with the comparative 
analysis of mitochondrial proteins from lean and obese insulin resistant subjects by high-
performance liquid chromatography–electrospray ionization–tandem mass spectrometry 
pointing out to a lower content in obese-insulin resistant subjects for some of the complex I 
subunits, less carnitine palmitoyltransferase 1B (key enzyme for fatty acid oxidation) and 
lower content of enzymes involved in branched amino acid metabolism. These differences in 
skeletal muscle mitochondrial proteins from lean and obese-insulin resistant subjects could 
explain why there is a higher intra-myocellular lipid accumulation in insulin resistant 
muscles, a higher ROS production and an improper branched amino acid oxidation (Lefort 
et al., 2010). Another issue that had not been previously addressed was mitochondrial 
sensitivity (mitochondrial respiratory performance under submaximal concentrations of 
substrates). This point was addressed by Dela and co-workers in T2DM subjects, obese 
controls and age-matched lean individuals. T2DM subjects showed enhanced mitochondrial 
substrate sensitivity when compared to obese controls. This better mitochondrial substrate 
handling is limited to non-lipid substrates (malate, glutamate, and succinate) and it is 
unrelated with maximal respiratory capacity, due to the fact that maximal oxidation rates 
were the same for the different substrates and experimental groups under assessment 
(Larsen et al., 2011). 
More information, discounting the hypothesis linking mitochondrial dysfunction with the 
pathogenesis of insulin resistance and subsequently T2DM, arrives from studies of low birth 
weight (LBW) individuals. It has been previously established that LBW is a risk factor of 
insulin resistance and T2DM (Phillips, 1998). A recent study by Brons et al. showed that 
young lean LBW subjects had abnormal glucose metabolism when compared to normal 
birth weight (NBW) controls, but skeletal muscle mitochondrial ATP production (both in 
arms and legs) and expression of oxidative phosphorylation genes were similar between 
LBW and NBW subjects (Brons et al., 2008). More clear evidence against the theory that 
mitochondrial dysfunction leads to insulin resistance and T2DM was supplied in a follow-
up study (Brons et al., 2012). Brons and co-workers assessed skeletal muscle mitochondrial 
function in LBW and NBW subjects before and after 5 days of high fat diet overfeeding. 
LBW subjects developed peripheral insulin resistance after high fat diet overfeeding but 
without any detrimental effect on mitochondrial oxidative capacity (Brons et al., 2012). 
7.2.1. Differences in between skeletal muscles, aerobic capacity and aging 
The comparison of mitochondrial function in arm and leg skeletal muscles from obese 
control and T2DM subjects supplies additional and relevant information to determine 
whether mitochondrial dysfunction is implicated in T2DM etiology. Mitochondrial 
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respiration, when quantified per milligram of wet tissue or citrate synthase activity, was 
similar in permeabilized muscle fibers from deltoids muscle biopsies of T2DM and obese-
control subjects. However, when mitochondrial respiration was measured from the vastus 
lateralis muscle a significant reduction was observed in T2DM subjects, as previously 
reported in other studies (Rabol et al., 2010). These results highlight the importance of 
assessing the physical fitness of the individuals, as this factor could explain the differences 
found in leg muscles oxidative capacity when healthy individuals and T2DM subjects are 
compared. The finding that muscle respiratory capacity is not impaired in arm muscles of 
T2DM subjects goes against the hypothesis of mitochondrial dysfunction playing a role in 
the pathogenesis of T2DM. More insight into this question was obtained in studies on aging, 
both in skeletal muscle insulin sensitivity and mitochondrial function. Karakelides and co-
workers performed a study assessing insulin sensitivity and skeletal muscle mitochondrial 
function using a hyperinsulinaemic-euglycemic clamp technique and quantification of 
mitochondrial ATP production rate, respectively (Karakelides et al., 2010). The subjects were 
divided in four different groups: young lean, young obese, old lean, and old obese 
individuals and stratified by sex. The results obtained by this experimental approach 
indicated that insulin sensitivity is related to the levels of adiposity and not to aging. In 
contrast, skeletal muscle mitochondrial function is reduced by age and not related to the 
levels of adiposity. Furthermore, men showed a higher mitochondrial ATP production rate 
than women, but women were more insulin sensitive than men. Taken together, this study 
clearly dissociated skeletal muscle mitochondrial function from insulin sensitivity 
(Karakelides et al., 2010). However, the subjects were not matched by maximal oxygen 
uptake capacity (VO2max.), which could be a confounding factor due to the fact that aerobic 
capacity is related to mitochondrial respiratory capacity. A recent study addressed whether 
aging has an effect in mitochondrial function when VO2max. values are taken into account. 
Young and middle-aged individuals with matched VO2max. had similar skeletal muscle 
mitochondrial respiratory capacity per wet tissue weight. However, when mitochondrial 
respiratory capacity was normalized by mitochondrial content, middle-aged subjects 
showed a lower capacity per mitochondrial unit (assessed by mtDNA content), implying 
that with age skeletal muscle keeps mitochondrial respiratory capacity increasing 
mitochondrial density (Larsen et al., 2012). 
7.2.2. Ethnicity and skeletal muscle insulin resistance 
It is known that Asian-Indians have one of the highest prevalence of T2DM in the world. In 
order to understand the metabolic differences that lead to this higher prevalence, a study 
was performed by Nair and co-workers comparing diabetic Asian-Indians, non-diabetic 
Asian-Indians, and non-diabetic Northern European-Americans (Nair et al., 2008). A 
hyperinsulinaemic-euglycemic clamp assessing insulin sensitivity and whole body glucose 
disposal, along with skeletal muscle maximal mitochondrial ATP production rate, protein 
content and mRNA expression information of different mitochondrial markers was used to 
evaluate mitochondrial function in the three experimental groups. Diabetic Asian-Indians 
and non-diabetic Asian-Indians had similar mitochondrial function even though they had 
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marked differences in insulin sensitivity, an observation that does not support 
mitochondrial dysfunction playing a role in T2DM development. Moreover, when the two 
ethnicities were compared, Asian-Indians had a higher OXPHOS capacity than Northern 
European-Americans even though Northern European-Americans were more insulin 
sensitive, providing additional data against a causative role of mitochondrial dysfunction in 
T2DM etiology (Nair et al., 2008).  
7.2.3. Lifestyle interventions in type 2 diabetic individuals 
It has been shown that lifestyle interventions that achieve significant body weight loss, 
reduction of body fat content, and improved aerobic capacity, are one of the most important 
tools, if not the best, in the prevention or amelioration of T2DM (Knowler et al., 2002). After 
completing an exercise training regime (cycling on a cycloergometer for 45 minutes, twice a 
week, for 10 weeks), T2DM subjects showed improved skeletal muscle lipid oxidation and 
mitochondrial oxidative capacity (Bordenave et al., 2008). However, this study did not 
address whether this significant improvement in mitochondrial function was related to 
enhanced glucose homeostasis, skeletal muscle insulin resistance, or both. Meex and co-
workers attempted to elucidate whether an exercise training regime (12 weeks of aerobic 
exercise) could have a positive effect on skeletal muscle mitochondrial dysfunction, elevated 
intra-myocellular lipid accumulation, and insulin resistance, characteristic features for 
T2DM (Meex et al., 2010). After the completion of the exercise training intervention both 
overweight controls and T2DM subjects showed improved insulin-mediated glucose 
disposal, and a significant increase in mitochondrial respiratory capacity measured by 31P-
magnetic resonance spectroscopy (Meex et al., 2010) and in permeabilised muscle fibers by 
high resolution respirometry (Phielix et al., 2010). T2DM subjects recovered metabolic 
flexibility and showed an increase in intra-myocellular lipid content, in relation with what 
had been observed in trained individuals and in disagreement with the hypothesis that 
increased skeletal muscle lipid storage is related to insulin resistance and mitochondrial 
dysfunction (Meex et al., 2010). Similar observations were obtained by Hey-Mogensen and 
co-workers in obese subjects with and without T2DM (Hey-Mogensen et al., 2010). After 10 
weeks of aerobic training both experimental groups showed significant improvement in 
mitochondrial respiratory capacity despite the observation of significant differences in 
insulin sensitivity between both groups (Hey-Mogensen et al., 2010). Obese subjects with 
T2DM showed increased reactive oxygen species (ROS) production (Hey-Mogensen et al., 
2010), which is in line with the results of Lefort and co-workers in a similar group of subjects 
(Lefort et al., 2010). Obese T2DM subjects that follow a lifestyle intervention program 
combining caloric restriction (25% reduction of daily energy intake) with regular physical 
activity (30-40 min aerobic exercise per session) achieved an approximately 7% weight 
reduction after four months. These individuals improved skeletal muscle mitochondrial 
density, citrate synthase activity and insulin sensitivity. Thus, proving that lifestyle 
interventions have a beneficial effect in the treatment of T2DM (Toledo et al., 2007). A 
follow-up study from the same research group (Toledo et al., 2008) attempted to discern 
whether mitochondrial improvement after weight loss due to a lifestyle intervention is 
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related to the decrease in body weight or requires the improvement in aerobic fitness 
obtained by regular exercise. Both intervention groups (diet alone and diet plus exercise) 
achieved the same body weight loss (10%) and similar insulin sensitivity improvements. 
However, only the subjects under the diet plus exercise intervention program showed a 
significant enhancement in mitochondrial function (Toledo et al., 2008). This observation is 
pertinent because it distinguishes between insulin resistance improvements and skeletal 
muscle mitochondrial performance. 
Human studies have produced clear evidence that T2DM is associated with skeletal muscle 
mitochondrial dysfunction, but have not supported the claim that mitochondrial 
dysfunction plays a major role in the development of the disease. It seems more likely that 
mitochondrial dysfunction could be a consequence of the general metabolic disarrangement 
originated in most cases by nutrient oversupply and insulin resistant status. As detailed 
before, skeletal muscle mitochondrial function is most probably modulated by the aerobic 
capacity of the individual, sex, age and ethnicity. 
7.3. Animal studies 
We have already mentioned that rats (Garcia-Roves et al., 2007, Hancock et al., 2008) and 
mice (Turner et al., 2007) develop insulin resistance with increased skeletal muscle 
mitochondrial content and fatty acid oxidative capacity after following a HFD for several 
weeks. These studies provided one of the first experimental evidences to show a 
discrepancy between mitochondrial dysfunction and T2DM etiology. However, at the same 
time a study was published by Lionetti and co-workers (Lionetti et al., 2007) in which rats 
were fed either with a low-fat diet or HFD for 7 weeks. The results obtained in this research 
showed how HFD induced hyperglycemia in rats and that it was related to an elevated fat 
supply, but not to higher energy uptake. Moreover, derangements in glucose handling are 
associated with a lower functionality of the subsarcolemmal mitochondrial population in 
skeletal muscle. This observation is in line with mitochondrial dysfunction playing a role in 
the development of T2DM and is also in agreement with a human study performed by Ritov 
and co-workers (Ritov et al., 2005). 
To decipher the role played by skeletal muscle mitochondria in T2DM etiology, De Feyter and 
co-workers (De Feyter et al., 2008) compared obese ZDF rats to lean controls. These groups 
were studied at 6, 12 and 18 weeks of age, going from a pre-diabetic state (week 6) to T2DM 
(week 12 and 18). Mitochondrial function (measured in vivo by magnetic resonance 
spectroscopy and in vitro by enzymatic activities) together with intra-myocellular lipid content, 
fasting plasma glucose, insulin and free fatty acids data were collected. All these results 
showed how T2DM develops in line with increased intra-myocellular lipid accumulation but 
without a decrease in skeletal muscle mitochondrial function, again showing a clear 
divergence between T2DM and skeletal muscle mitochondrial function (De Feyter et al., 2008). 
These observations were corroborated in later studies by the same research group where 
mitochondrial respiratory capacity was measured by high-resolution respirometry (Lenaers et 
al., 2010). A similar analytical approach was also performed in mice fed with a HFD for 4 
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weeks (Bonnard et al., 2008) with similar results to those reported by De Feyter and co-
workers (De Feyter et al., 2008), highlighting that mitochondrial dysfunction did not precede 
insulin resistance. However, when mice were fed with HFD for a longer term (16 weeks), 
mitochondrial defects were evident and mitochondrial respiration rates were lower in 
permeabilized muscle fibers. Mitochondrial defects were related to a higher ROS production 
rate and it was shown that a supplementation with antioxidants restored mitochondrial 
defects (Bonnard et al., 2008). Similar observations were made by Yokota and co-workers 
(Yokota et al., 2009) in mice fed with a HFD for 8 weeks. In Yokota’s study they attempted to 
assess if insulin resistant mice with higher ROS production and impaired mitochondrial 
dysfunction would have a reduced exercise performance and whether antioxidant 
supplementation could reverse the adverse effect on exercise performance. When mice on a 
HFD were supplemented with apocynin, a compound that reduce free radical formation by 
inhibition of NAD(P)H oxidase activity (which reduces oxygen to superoxide), mice showed 
similar mitochondrial function, ROS production and exercise performance that mice under a 
low fat diet (LFD). However, these mice (HFD+apocynin), despite having better mitochondrial 
function, still showed impaired glucose tolerance (Yokota et al., 2009). 
A subsequent study used Zucker rats to evaluate whether fatty acid transport played a key 
role in the observed increase in intra-myocellular fatty acid accumulation (Holloway et al., 
2009). Additionally, fatty acid oxidation rates, mitochondrial density and intra-muscular 
triacylglycerol content were also determined. In summary, this study showed how skeletal 
muscle fatty acid transport was increased, mainly trough an upregulation of the levels of the 
fatty acid transporter CD36 (Holloway et al., 2009). Skeletal muscle subsarcolemmal 
mitochondria were increased and had a higher capacity to oxidize fatty acid, in contrast to 
previous observations (Ritov et al., 2005, Lionetti et al., 2007). However, based on their in 
vitro studies, fatty acid transport exceeded mitochondrial fatty acid oxidative capacity and 
therefore, intra-myocellular lipid accumulation was increased, which in a long term could 
explain skeletal muscle metabolic derangements observed in obesity and T2DM (Holloway 
et al., 2009). 
Another aspect of lipid oversupply related to insulin resistance is the saturation of the 
phospholipids (fatty acid composition), which could alter membrane properties and 
therefore cellular function. Thus, insulin resistance correlated with the level of membrane 
phospholipids in skeletal muscle of Pima Indians, a population with the highest T2DM 
incidence (Pan et al., 1995). On this respect, two recent studies have addressed whether 
phospholipid fatty acid composition affects mitochondrial function and whether this is the 
mechanism leading to insulin resistance and further T2DM. For this purpose, C57BL/6J mice 
were fed with a LFD or a HFD for 3 or 28 days, and fasting glucose, insulin, gene expression 
profile, mitochondrial proteins and lipid composition were determined at each time point (3 
and 28 days). After day 3, mice on a HFD showed increased fasting blood glucose and 
insulin levels. A marked increase in protein content of the different mitochondrial OXPHOS 
complexes was also observed at day 28 along with an increase in the degree of 
phospholipids saturation (de Wilde et al., 2008). Later on, the same research group 
attempted to understand whether mitochondrial membrane phospholipids composition 
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could affect mitochondrial function. In this study C57BL/6J mice were fed with a LFD or 
HFD for 8 or 20 weeks. From week 8, mice on a HFD had a higher level of saturation in their 
skeletal muscle mitochondrial membrane phospholipids. Mice were insulin resistant 
although mitochondrial respiratory capacity was not affected. Therefore, these observations 
were against mitochondrial dysfunction being a key feature in T2DM etiology and also 
questioning the role played by phospholipids composition in mitochondrial performance 
and glucose handling (Hoeks et al., 2011).  
It seems clear, from the information obtained in the different studies using HFD-induced 
insulin resistance in mice or rats that at earlier and intermediate stages there are 
mitochondrial adaptations that improve skeletal muscle oxidative capacity to overcome 
fatty acid oversupply. To maintain skeletal muscle oxidative capacity, mitochondrial density 
is increased as showed by Van den Broek and co-workers (van den Broek et al., 2010) and in 
line with the observation made in humans by Dela and co-workers (Larsen et al., 2012). 
7.4. Conclusions 
Over these years we have reached a better understanding of how skeletal muscle 
mitochondria respond to different pathophysiological conditions. The evidence also clearly 
indicated that, at least at later stages in the etiology of the disease, mitochondrial 
dysfunction is present in T2DM both in humans and in animals. However, mitochondrial 
dysfunction does not play a major role in skeletal muscle insulin resistance and the 
development to T2DM. Most probably mitochondrial dysfunction results from the different 
disturbances produced by nutrient oversupply and lack of physical activity characteristic of 
the sedentary lifestyle of modern societies. Skeletal muscle mitochondrial function will be 
influenced by age, sex, ethnicity, and aerobic capacity. And more importantly, skeletal 
muscle mitochondrial defects and insulin resistance characteristic of T2DM could be rescue 
by changes in lifestyle that lead to an improved physical fitness and balanced diet. 
7.5. Future perspectives 
T2DM is a complex metabolic disease that involves disturbances not only in skeletal muscle, 
liver and pancreatic beta-cells (Defronzo, 1988) but also implies malfunction of adipose 
tissue, pancreatic alpha-cells, kidney, gastrointestinal tract and brain (Defronzo, 2009). 
Therefore, with the aim to find how to successfully prevent or treat T2DM we should 
address our research taking into account the systemic nature of this metabolic disease. 
All cell types present in our body have a lower or higher degree of specialization that will 
determine their metabolic requirements and ability to adapt to different physiological or 
pathophysiological stresses. Thus, mitochondrial plasticity to metabolic derangements are 
cell-type specific. In this regard, Garcia-Roves and co-workers showed how different tissues 
respond differently to obesity and T2DM in terms of mitochondrial adaptive capacity 
(Holmstrom et al., 2012). Thus, db/db mice, an animal model of diabetes and obesity, 
showed clear evidence of mitochondrial dysfunction in liver at 16 weeks of age. However, 
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glycolytic skeletal muscles from the same mice had a better mitochondrial respiratory 
capacity and mitochondrial content than the lean control mice. More importantly, oxidative 
skeletal muscles show earlier evidences of mitochondrial function impairment. This study 
brings into account cell type plasticity and that time is also very important in the 
development of T2DM and should be taken into account to better interpret the different 
results already published (Holmstrom et al., 2012). 
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